Navigation Links
Meditrina Pharmaceuticals, Inc. Opens Investigational New Drug (IND) Application for Phase IIb Clinical Trial With MPI-676 in Endometriosis
Date:7/17/2008

- Approval of Second IND Marks Major Corporate Milestone and Advances

Clinical Program -

ANN ARBOR, Mich., July 17 /PRNewswire/ -- Meditrina Pharmaceuticals, Inc. today announced the approval of its second investigational new drug (IND) application for a Phase IIb dose ranging clinical trial to study MPI-676, the Company's aromatase inhibitor (AI), in combination with estrogen and progestin for the treatment of endometriosis. MPI-676 is the newest addition to Meditrina's clinical stage product portfolio that currently includes Femathina(TM) (MPI-674), an AI that Meditrina is repurposing for the treatment of endometrial thinning prior to endometrial ablations in premenopausal women with abnormal uterine bleeding. Meditrina recently completed a global licensing agreement to make, develop and commercialize products, including MPI-676, under AstraZeneca's IP and know-how regarding the use of AIs in combination with estrogen and progestin to treat endometriosis.

"This IND for MPI-676 marks another major milestone in our robust clinical program focused on addressing women's reproductive system disorders," said James Symons, Ph.D., Vice President, Clinical Development, Meditrina Pharmaceuticals, Inc. "Based on the encouraging proof of concept and strong safety data established for MPI-676, we look forward to selecting the dose for Phase III pivotal trials, which will be at a dose lower than for which AstraZeneca has already established two-year chronic use safety data in their breast cancer prevention trials and is cited in the anastrozole product label. These data will advance development of MPI-676 and help us bring this important new treatment to women suffering from endometriosis, a painful and debilitating condition."

This US-based, multi-center, placebo-controlled, double-blinded study will identify the maximally efficacious dose of MPI-676 to investigate in the pivotal Phase III program. The Phase IIb dose ra
'/>"/>

SOURCE Meditrina Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
2. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
3. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
4. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
5. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
6. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
7. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
8. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
9. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... , Aug. 19, 2014  The Alabama Supreme Court, in ... can sue drug makers who mislead doctors into believing that ... The case is Weeks v. Wyeth, and the decision came ... that same case last year. Heninger Garrison Davis attorneys ... patient in the case, Danny Weeks . ...
(Date:8/19/2014)... , Aug. 19, 2014 Minimally Invasive ... medical device company, announced today that Mitsubishi Corporation ... and robotic visualization system in Japan ... sale in Japan in the ... also the exclusive distributor for Karl Storz GMBH & ...
(Date:8/19/2014)... Aug. 19, 2014  As power morcellator lawsuits ... Bernstein Liebhard LLP notes that women in need ... a number of options that do not involve ... According to a report published by The Wall ... options include a mini-laparotomy and vaginal hysterectomy. Non-surgical ...
Breaking Medicine Technology:Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 2Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 3Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 4Minimally Invasive Devices and Mitsubishi Medical Japan Forge Exclusive Distribution Agreement 2As Morcellator Lawsuits Mount, Bernstein Liebhard LLP Notes Report Detailing Alternatives to Uterine Morcellation 2As Morcellator Lawsuits Mount, Bernstein Liebhard LLP Notes Report Detailing Alternatives to Uterine Morcellation 3
... , Jan. 25 Curemark, LLC , ( www.curemark.com ... neurological diseases, announced that the company is now enrolling patients in Phase ... the country.  The sites are: , Mount Sinai School of Medicine, ... University of Texas, Houston Indiana University, ...
... , MELVILLE, N.Y. , Jan. 25 ... the largest distributor of health care products and services to office-based ... Bradley T. Sheares , Ph.D. to the Company,s Board of Directors. ... a wealth of health care experience to the Henry Schein Board. ...
Cached Medicine Technology:Curemark Enrolling Patients In Phase III Autism Trials At Ten Sites 2Curemark Enrolling Patients In Phase III Autism Trials At Ten Sites 3Curemark Enrolling Patients In Phase III Autism Trials At Ten Sites 4Henry Schein Elects Dr. Bradley T. Sheares to Board of Directors 2Henry Schein Elects Dr. Bradley T. Sheares to Board of Directors 3Henry Schein Elects Dr. Bradley T. Sheares to Board of Directors 4Henry Schein Elects Dr. Bradley T. Sheares to Board of Directors 5
(Date:8/20/2014)... B. E. Smith, the only full-service leadership solutions ... to lead a national chief operating officer ... Ore. The top executive search firm in ... more than 900 healthcare executives into organizations. , ... healthcare organization serving a population of more than 35,000 ...
(Date:8/20/2014)... Hope For The Warriors® is excited to announce ... in Washington, DC on Thursday, October 2, 2014 at ... the courage of our wounded service members, their families, ... Got Heart, Give Hope® Celebration will benefit Hope For ... sense of self, restoring the family unit, and restoring ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Inc. ... year on its 33rd annual Inc. 500|5000, an ... The list represents the most comprehensive look at ... entrepreneurs. Companies such as Yelp, Pandora, Timberland, Dell, ... names gained early exposure as members of the ...
(Date:8/20/2014)... Atlanta, GA (PRWEB) August 20, 2014 ... Data to healthcare, Jvion successfully predicted stage iii ... levels that, in some situations, approached 90%. A ... never been achieved in commercial or academic settings. ... and prevent all types of hospital-acquired conditions to ...
(Date:8/20/2014)... Ticketability.com has Theresa Caputo tickets for ... well-known medium has been thrilling many with her amazing ... cities, with tickets becoming available August 15. , Among ... Albany, Baltimore, Trenton, Erie, Buffalo, Philadelphia, Charlotte, Houston, New ... Diego. The medium’s fans can obtain Theresa Caputo tour ...
Breaking Medicine News(10 mins):Health News:Good Shepherd Health Care System Retains B. E. Smith to Recruit New COO 2Health News:Good Shepherd Health Care System Retains B. E. Smith to Recruit New COO 3Health News:Hope For The Warriors Announces Got Heart, Give Hope Celebration in Washington, DC 2Health News:Etransmedia Makes Exclusive List for the Eighth Consecutive Year in Inc. Magazine 2Health News:Etransmedia Makes Exclusive List for the Eighth Consecutive Year in Inc. Magazine 3Health News:Jvion Achieves Benchmark Accuracy in Pressure Ulcer Prediction 2Health News:Theresa Caputo Tour Tickets for Sale at Ticketability.com Cause a Buying Frenzy Among Customers Over Their Offering of Deeply Discounted Seats 2
... treatment mainstay for prostate cancer puts men at increased ... large observational study published in the// Sept. 20 Journal ... have high five-year survival rates, but they also have ... study author Nancy Keating, MD, MPH, assistant professor of ...
... Chile announced a tax on airline tickets to raise ... who cannot afford them//. ,Representatives from the five ... Ignacio Lula da Silva of Brazil, were present for ... Annan and former US President Bill Clinton also attended. ...
... are almost twice as likely to attempt suicide as non-Maori ... than other New Zealanders. ,The survey conducted by the ... the prevalence of mental disorders among different ethnic groups in ... including 2600 Maori. ,It was found that thirty percent ...
... Recent studies have revealed that increased levels of ... events// in healthy women according to Boston-based investigators. ... screening of lipoprotein(a) in the population as a ... with cardiovascular risk. Besides that most lipid-correcting therapies ...
... tested as an anticancer agent to treat breast cancer, supports ... ,Duchene muscular dystrophy is a disease characterized by ... According to earlier studies, the functional decline of "dystrophic" ... fiber size. ,The recent study conducted by Dr. ...
... (China): More than 200 children were taken ill after eating ... ,The 223 students were admitted to a hospital and are ... ,Students of Dianshi Town High School began reporting symptoms ... at their school Monday and were immediately hopitalised. ...
Cached Medicine News:Health News:Prostate Cancer Treatment Increases Risk of Diabetes and Heart Disease 2Health News:High lipoprotein Levels in women Linked to Cardiovascular Risk 2Health News:Anti-cancer drug may treat muscular dystrophy 2
... The HSV Non-Typing ASR contains primers and ... a 92 bp region of the HSV Type ... requires an instrument that can detect a FAM ... The Cepheid Analyte Specific Reagent* (ASR) program is ...
... compact system is perfect for the office, ... cost effective microhematocrits are required. Featuring a ... offers a range of important benefits: - ... Meets NCCLS standards - Read tubes in ...
... Palomar systems deliver pulsed light over ... multiple power spikes (which may damage skin) ... Cooling technology sends a chilled water supply ... sapphire tip, which is cooled to as ...
Used to provide drainage of urine from the bladder. All-silicone construction provides maximum softness and biocompatibility for enhanced patient comfort. Supplied sterile in peel-open packages. Inte...
Medicine Products: